ResApp Health Limited announced that it has signed a six-month joint development and pilot agreement with Medgate AG to integrate and test ResApp's smartphone-based acute respiratory diagnostic test ResAppDx in Medgate's telemedicine services. Medgate and ResApp will work together to build and pilot an integration of ResAppDx in the Medgate services. The integration phase of the project, which covers both technical integration and clinical workflows, is expected to take two months, with a three-month pilot period to evaluate the integration expected to begin in early 2021. During the pilot phase, ResApp and Medgate will jointly assess the impact of ResAppDx on Medgate's telehealth service through a number of key performance indicators. During the pilot, ResApp and Medgate expect to enter into negotiations on the cost model of using ResAppDx on Medgate's telehealth service. ResApp will not receive material revenue from the pilot project. Either party may terminate the joint development and pilot agreement by providing 30 days' notice.